Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Coding Corner Answer: December Coding Challenge

Staff  |  Issue: December 2012  |  December 1, 2012

Test Your Coding Skills for the Certified Rheumatology Coder Course and Exam…

  1. D: High: The patient has one established problem worsening—severe rheumatoid arthritis—and one new problem with work up—adverse reaction to infusion. The amount of data reviewed or ordered was none. The patient’s level of risk was high because the patient has severe rheumatoid arthritis.
  2. C: 96413: The infliximab infusion was 35 minutes along before it was stopped because of an adverse reaction. The first hour of an infusion must be at least 16 minutes long in order to qualify as an infusion. If the first hour is less than 16 minutes, it must be coded as a chemotherapy push—96401. Descriptions of each code are below:
    • 96413—Chemotherapy administration, intravenous infusion technique; up to one hour, single or initial substance/drug
    • 96401—Chemotherapy administration, subcutaneous or intramuscular, nonhormonal antineoplastic
  3. C: 96375: The push would be coded as a subsequent push because only one initial code in the drug administration family—96413—can be billed during a session.
    • 96375—each additional sequential intravenous push of a new substance/drug (list separately in addition to code for primary procedure)
  4. D: 96361-59: As stated in answer three above, only one initial code is allowed per session. The infusion of hydration is only allowed if the saline is used to remove the drug from a patient in the case of an adverse reaction. The modifier -59 is required to get this charge reimbursed.
  5. C: 20: The code for the infliximab is 20—J1745 10 mg. To arrive at the number of units to be billed, divide 200 mg—the amount of the drug used—by 10.
    • J1745–Injection, infliximab, 10 mg

Share: 

Filed under:Billing/CodingConditionsPractice SupportRheumatoid Arthritis Tagged with:BillingCodingdruginfliximabPractice ManagementRheumatoid arthritisrheumatologist

Related Articles

    Coding Corner Answer: August Coding Challenge

    August 8, 2012

    A 43-year-old female established patient diagnosed with rheumatoid arthritis comes to the office for her first infliximab infusion.

    Coding Corner Answer: July Coding Challenge

    July 1, 2013

    Coding for a patient who gets subsequent infusions of infliximab

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    August 16, 2019

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    Coding Corner Answer: March

    March 1, 2015

    Coding for chemotherapy infusion with a drug reaction

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences